Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | LOX | P28300 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961463 | 0.89 | MAPK14 (0.58) | MAPK14RIPK2MAPKAPK2PTPN1RAB9A | |
| SCHEMBL3296237 | 0.88 | PTPN1 (0.79) | MAPK14RIPK2MAPKAPK2PTPN1RAB9A | |
| SCHEMBL23723511 | 0.85 | RIPK2 (0.65) | MAPK14RIPK2MAPKAPK2PTPN1RAB9A | |
| SCHEMBL30120709 | 0.85 | RIPK2 (0.65) | MAPK14RIPK2MAPKAPK2PTPN1RAB9A | |
| SCHEMBL1692019 | 0.83 | RIPK2 (0.71) | MAPK14RIPK2MAPKAPK2PTPN1RAB9A | |
| SCHEMBL1356015 | 0.82 | ALDH1A1 (0.79) | MAPK14PTPN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2804588 | 0.80 | RIPK2 (0.71) | MAPK14RIPK2PTPN1RAB9ASMN1; SMN2 | |
| SCHEMBL4696735 | 0.80 | RIPK2 (0.71) | MAPK14RIPK2PTPN1RAB9ASMN1; SMN2 | |
| SCHEMBL3830233 | 0.80 | RIPK2 (0.71) | MAPK14RIPK2PTPN1RAB9ASMN1; SMN2 | |
| SCHEMBL2743084 | 0.80 | RIPK2 (1.00) | MAPK14RIPK2RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2010118367-A2 | ANTIVIRAL PYRIMIDINES | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | disclosed |
| US-4920119-A | XANTHINE OXIDASE INHIBITORS; CONTROL OR PREVENTION OF GOUT OR ISCHEMIA | HOFFMANN-LA ROCHE INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0274654-A2 | 1,2,3-Triazin-4(3H)-one derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE AG (CH) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | MAPK14 4823/4885RIPK2 4695/4885MAPKAPK2 4841/4885 |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | MAP4K2, MAP4K3, MAP4K1 | MAPK14 47/4885RIPK2 292/4885MAPKAPK2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.